UNRESECTABLE PANCREATIC CARCINOMA
Clinical trials for UNRESECTABLE PANCREATIC CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE PANCREATIC CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE PANCREATIC CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis study tests two experimental drugs, ZEN003694 and entinostat, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The trial includes up to 49 participants,…
Matched conditions: UNRESECTABLE PANCREATIC CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:46 UTC
-
Experimental cocktail aims to shrink untreatable pancreatic tumors
Disease control Recruiting nowThis early-phase study tests whether adding bosentan to standard chemotherapy can help control pancreatic cancer that cannot be removed by surgery. About 21 adults will receive the combination to find the safest dose and check for side effects. The goal is to slow or stop tumor g…
Matched conditions: UNRESECTABLE PANCREATIC CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New cocktail of targeted drug, immunotherapy, and radiation takes on tough pancreatic cancer
Disease control Recruiting nowThis early-stage trial tests whether combining a targeted drug (olaparib), an immunotherapy (durvalumab), and radiation therapy is safe for people with locally advanced pancreatic cancer that cannot be surgically removed. About 18 participants will receive the combination after i…
Matched conditions: UNRESECTABLE PANCREATIC CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New drug combo targets Hard-to-Treat GI cancers
Disease control Recruiting nowThis study is for people with advanced or metastatic gastrointestinal cancers, including anal and pancreatic cancers. Researchers are testing a combination of two drugs, pelareorep and atezolizumab, to see if they are safe and can shrink tumors or slow disease growth. About 122 p…
Matched conditions: UNRESECTABLE PANCREATIC CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Oncolytics Biotech • Aim: Disease control
Last updated May 13, 2026 16:01 UTC